Cancer cachexia is a devastating wasting syndrome that significantly restricts therapeutic options for cancer patients. The development of treatments has been limited by a lack of in-depth ...

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

An Israeli-American study has uncovered a key mechanism behind cachexia, offering hope to the estimated nine million people suffering from the deadly syndrome that causes severe weight and muscle loss ...

A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...

Cachexia is a "wasting" disorder that leads to involuntary weight loss and muscle wasting, often including fat loss. It is a ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...